Liver damage in patients with ischemic chronic heart and type 2 diabetes - a treacherous tandem: possible additional organoprotective therapy
- Authors: Statsenko M.E1, Turkina S.V1, Shilina N.N1
-
Affiliations:
- Volgograd State Medical University of Ministry of Health of the Russian Federation
- Issue: Vol 18, No 5 (2016)
- Pages: 103-109
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/94512
- ID: 94512
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
M. E Statsenko
Volgograd State Medical University of Ministry of Health of the Russian Federation
Email: mestatsenko@rambler.ru
д-р мед. наук, проф., зав. каф. внутренних болезней педиатрического и стоматологического фак-тов ГБОУ ВПО ВолгГМУ 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1
S. V Turkina
Volgograd State Medical University of Ministry of Health of the Russian Federationд-р мед. наук, проф. каф. внутренних болезней педиатрического и стоматологического фак-тов ГБОУ ВПО ВолгГМУ 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1
N. N Shilina
Volgograd State Medical University of Ministry of Health of the Russian Federationканд. мед. наук, ассистент каф. внутренних болезней педиатрического и стоматологического фак-тов ГБОУ ВПО ВолгГМУ 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1
References
- Nieminen M.S, Brutsaert D, Dickstein K et al. Euro Heart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725-36.
- Bertoni A.G, Hundley W.G, Massing M.W et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699-703.
- Sarma S, Mentz R.J, Kwasny M.J et al. On behalf of the EVEREST investigators. Association between diabetes mellitus and post - discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 2013; 15: 194-202.
- Shengbo Y. The prevalence and prognostic value of liver function abnormalities in patients with chronic systolic heart failure. Heart 2011; 97: А215.
- Ballestri S, Lonardo A, Bonapace S et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20 (7): 1724-45.
- Ekstedt M, Franz´en L.E, Mathiesen U.L et al. Long - term follow - up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
- Dogan S, Celikbilek M, Yilmaz Y.K et al. Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2015; 27 (3): 298-304.
- Kim D, Kim W.R, Kim H.J, Terry M. Therneau. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57 (Issue 4): 1357-65.
- Ban C.R, Twigg S.M. Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag 2008; 4 (3): 575-96.
- Dries D.L, Sweitzer N.K, Drazner M.H et al. Prognostic Impact of Diabetes Mellitus in Patients With Heart Failure According to the Etiology of Left Ventricular Systolic Dysfunction. J Am Coll Cardiol 2001; 38 (2): 421-8.
- Xu Y.J, Saini H.K, Zhang M et al. MAPK activation and apoptotic alterations in hearts subjected to calcium paradox are attenuated by taurine. Cardiovasc Res 2006; 72: 163-74.
- Schaffer S.W, Lombardini J.B, Azuma J. Interaction between the actions of taurine and angiotensin II. Amino Acids 2000; 18: 305-18.
- Abebe W, Mozaffari M.S. Role of taurine in the vasculature: an overview of experimental and human studies. Am J Cardiovasc Dis 2011; 1 (3): 293-311.
- Стаценко М.Е., Туркина С.В., Шилина Н.Н., Винникова А.А. Место таурина в комплексном лечении пациентов с хронической сердечной недостаточностью и сахарным диабетом 2 типа. Рус. мед. журн. 2015; 23 (8): 472-6.
- Abd El-Kader S.M, El-Den Ashmaw E.M.S. Non - alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7 (6): 846-58.
- Gentile C.L, Nivala A.M, Gonzales J.C et al. Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. Am J Physiol Regul Integr Comp Physiol 2011; 301 (6): R1710-R1722.
- Balkan J, Do ru-Abbaso lu S, Kanba li O et al. Taurine has a protective effect against thioacetamide - induced liver cirrhosis by decreasing oxidative stress. Hum Exp Toxicol 2001; 20: 251-4.
- Hansen S.H. The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab Res Rev 2001; 17: 330-46.
- Стаценко М.Е., Туркина С.В., Шилина Н.Н., Косивцова М.А. Особенности гепато - кардиальных взаимоотношений у пациентов с хронической сердечной недостаточностью и нарушениями углеводного обмена: возможности дополнительной терапии. Рус. мед. журн. 2015; 23 (21): 1293-7.
- Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 14; 7 (81): 1-94.
- Алгоритмы специализированной медицинской помощи больным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой. М., 2015.]
- Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology 2006; 6: 33-8.
- Angulo P, Hui J.M, Marchesini G et al. The NAFLD Fibrosis Score: A Noninvasive System That Identifies Liver Fibrosis in Patients with NAFLD. Hеpatology 2007; 45 (4): 846-54.
- Walczewska M, Marcinkiewicz J. Taurine chloramine and its potential therapeutical application. Przegl Lek 2011; 68 (6): 334-8.
- EASL-ALEH Clinical Practice Guidelines: Non - invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 1. doi: 10.1016/j.jhep.2015.04.006.
- Yokogoshi H, Mochizuki H, Nanami K et al. Dietary taurine enhances cholesterol degradation and reduces serum and liver cholesterol concentrations in rats fed a high - cholesterol diet. J Nutr 1999; 129: 1705-12.
- Murakami S, Yamagishi I, Asami Y et al. Hypolipidemic effect of taurine in stroke - prone spontaneously hypertensive rats. Pharmacology 1996; 52: 303-13.
- Unger R.H. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003; 14: 398-403.
- Carneiro E.M, Latorraca M.Q, Araujo E et al. Taurine supplementation modulates glucose homeostasis and islet function. J Nutr Biochemistry 2009; 20: 503-11.
- Maturo J, Kulakowski E.C. Taurine binding to the purified insulin receptor. Biochem Pharmacol 1988; 37 (19): 3755-60.
- Gavrovskaya L.K, Ryzhova O.V, Safonova A.F et al. Protective effect of taurine on rats with experimental insulin - dependent diabetes mellitus. Bull Exp Biol Med 2008; 146 (2): 226-8.
- Nakaya Y, Minami A, Harada N et al. Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes. Am J Clin Nutr 2000; 71 (1): 54-8.
- Wu N, Lu Y, He B et al. Taurine prevents free fatty acid - induced hepatic insulin resistance in association with inhibiting JNK1 activation and improving insulin signaling in vivo Diabetes Res Clin Pract 2010; 90 (3): 288-96.